Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Severe short stature, Sideways curvature of the spine (scoliosis), Anterior pituitary hypoplasia, and Decreased serum insulin-like growth factor 1 and others. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Growth and development | 4 | Severe short stature, Pituitary dwarfism, Decreased serum insulin-like growth factor 1 |
Hormones | 4 | Anterior pituitary hypoplasia, Pituitary dwarfism, Decreased serum insulin-like growth factor 1 |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
GH1 encodes growth hormone 1 (217 aa). Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF1. Highest expression in Pituitary (53,059 TPM) and Brain Cerebellum (5.3 TPM).
Isolated growth hormone deficiency type II is associated with mutations in the GH1 gene on chromosome 17.
GH1 is classified as a druggable target (Druggable Genome, Growth Factor, and Hormone Activity categories) with score 8.7.
Genetic testing for GH1 is available. Testing is considered confirmatory for diagnosis.
4 FDA-approved treatments are available for isolated growth hormone deficiency type II, including SOMATROGON-GHLA (NGENLA, approved 2023), LONAPEGSOMATROPIN-TCGD (SKYTROFA, approved 2021), and SOMAPACITAN-BECO (SOGROYA, approved 2020). An additional 7 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
NGENLA | SOMATROGON-GHLA | — | 2023 | Available |
SKYTROFA | LONAPEGSOMATROPIN-TCGD | — | 2021 | Available |
SOGROYA | SOMAPACITAN-BECO | — | 2020 | Available |
MACRILEN | MACIMORELIN ACETATE | — | 2017 | Available |
The following drugs have received orphan drug designation from the FDA for isolated growth hormone deficiency type II. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine | Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine | Hollenbeck Pharmaceuticals, Inc. | 2022 | — | Designated |
recombinant human growth hormone fused to alpha1-antitrypsin variant | recombinant human growth hormone fused to alpha1-antitrypsin variant | Alteogen, Inc. | 2019 | — | Designated |
Gene therapy approaches for isolated growth hormone deficiency type II have been reported in the published literature.
View trials for isolated growth hormone deficiency type II
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for isolated growth hormone deficiency type II.
6 publications have been identified in PubMed for isolated growth hormone deficiency type II. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (17%).
Song Y (2026). [PMID: 42028331](https://pubmed.ncbi.nlm.nih.gov/42028331/). *Pediatric Health Med Ther*. [Case Report / Case Series]
Li R (2025). [PMID: 39562420](https://pubmed.ncbi.nlm.nih.gov/39562420/). *Endocrine*. [Review / Meta-Analysis]
Ariyasu D (2025). [PMID: 39940828](https://pubmed.ncbi.nlm.nih.gov/39940828/). *Int J Mol Sci*. [Basic Science / Preclinical]
Radovick S (2025). [PMID: 40058338](https://pubmed.ncbi.nlm.nih.gov/40058338/). *Horm Res Paediatr*. [Gene Therapy / Novel Therapeutics]
Noorian S (2025). [PMID: 39980897](https://pubmed.ncbi.nlm.nih.gov/39980897/). *Clin Case Rep*. [Case Report / Case Series]
Huang X (2024). [PMID: 39435354](https://pubmed.ncbi.nlm.nih.gov/39435354/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 5:20 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
ibutamoren mesylate
ibutamoren mesylate |
Lumos Pharma LLC |
2017 |
— |
Designated |
recombinant growth hormone fused to hyFc | recombinant growth hormone fused to hyFc | Genexine, Inc. | 2016 | — | Designated |
growth hormone releasing hormone, 1-44 human amide | growth hormone releasing hormone, 1-44 human amide | Hollenbeck Pharmaceuticals, Inc. | 2016 | — | Designated |
recombinant human serum albumin human growth hormone | recombinant human serum albumin human growth hormone | TEVA Branded Pharmaceutical Products R&D, Inc. | 2016 | — | Withdrawn |
somavaratan | somavaratan | Versartis, Inc. | 2013 | — | Designated |